Novo Nordisk, OpenAI in broad AI drug pact

Novo Nordisk has announced a wide-ranging strategic partnership with OpenAI designed to accelerate how medicines are discovered, developed and delivered. The Danish drugmaker said on April 14, 2026, that the collaboration will place it at the forefront of AI transformation in healthcare and help bring new and better treatment options to patients faster.

Under the agreement, Novo Nordisk will integrate OpenAI’s most advanced AI capabilities across its global operations, spanning drug discovery, research and development, manufacturing, supply chain, distribution, and corporate functions. Financial terms of the deal were not disclosed.

The move builds on Novo Nordisk’s existing AI initiatives, including collaborations with technology partners and research organisations, and follows Novo Nordisk’s June 2025 announcement of the Gefion AI supercomputer built on NVIDIA DGX SuperPOD technology and other AI collaborations with NVIDIA.

Novo Nordisk said the partnership will use OpenAI’s technology to analyse complex genomic, biological and clinical datasets, identify promising drug candidates, and reduce the time required to move medicines from research to patient use. The company aims to shorten multiyear development cycles by using AI to find hidden patterns and simulate experiments that would otherwise need to be run in laboratories.

The collaboration is expected to support the development of new therapies for chronic diseases, including obesity and diabetes, areas where Novo Nordisk already specialises. Several reports noted that the company intends to speed the development of new obesity drugs and address what it described as significant unmet need among millions of people living with chronic illnesses.

According to Novo Nordisk President and CEO Mike Doustdar, integrating AI into everyday work will allow the company to analyse datasets at a previously impossible scale, identify patterns that were not visible before, and test hypotheses faster. He said this should help discover new therapies and bring them to market more quickly.

Beyond research, Novo Nordisk plans to apply OpenAI’s systems to improve efficiency in manufacturing, supply chains, and commercial operations, including distribution. The aim is to speed the time it takes to get medicines into the hands of patients and to run smarter global operations.

The partnership will begin with pilot programmes across research and development, manufacturing and commercial operations. Multiple sources stated that Novo Nordisk targets full integration of OpenAI’s capabilities by the end of 2026, extending the AI tools across its entire global footprint if initial projects prove successful.

Both companies said the collaboration is structured with strict data protection, governance and human oversight to ensure ethical and compliant use of AI, including an explicit data governance framework around AI-based decisions.

A core element of the agreement is workforce transformation. OpenAI will work directly with Novo Nordisk employees to upskill the global workforce, raise AI literacy and help teams build and use custom tools tailored to their roles.

Novo Nordisk said the goal is to empower staff to work smarter and faster, automating laborious tasks and freeing researchers and other employees to focus on higher-value work. Doustdar described the aim as “supercharging” scientists rather than replacing them.

He added that the partnership is not designed to cut the company’s current workforce, but to lift productivity and curb the pace of future hiring by enabling employees to work more efficiently.

The new alliance comes as drugmakers increasingly deploy AI to streamline tasks such as finding clinical trial participants, selecting study sites and preparing regulatory filings. Novo Nordisk said the OpenAI deal is an important step in positioning the company to lead in what it called the next era of healthcare.

OpenAI CEO Sam Altman said AI is reshaping industries and, in life sciences, can help people live better, longer lives. He stated that the collaboration is intended to accelerate scientific discovery, support smarter global operations and help redefine future patient care.

Multiple accounts emphasised that this is more than a standard software agreement, describing OpenAI’s role as embedding intelligent agents across Novo Nordisk’s workflows and working hands-on with staff to maximise the benefits of AI across the business.